EU CHMP adopts positive opinion for Keytruda plus chemo ± bevacizumab in persistent, recurrent, or metastatic cervical cancer expressing PD-L1 (CPS ≥1)

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.

March 13, 2026

Vol.52 No.10

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approved Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

February 27, 2026

Vol.52 No.08

Cancer Policy

FDA approves labeling changes to menopausal hormone therapy products

FDA has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy.

February 13, 2026

Vol.52 No.06

By Claire Marie Porter

Clinical Roundup

HPV cancer vaccine slows tumor growth, extends survival in animal models

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

February 13, 2026

Vol.52 No.06

EU CHMP adopts positive opinion for Keytruda plus chemo ± bevacizumab in persistent, recurrent, or metastatic cervical cancer expressing PD-L1 (CPS ≥1)

YOU MAY BE INTERESTED IN

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approves labeling changes to menopausal hormone therapy products

HPV cancer vaccine slows tumor growth, extends survival in animal models

Renew today!

Subscriber content

Never miss an issue!

Login